T1	Participants 89 138	patients with hormone-refractory prostate cancer.
T2	Participants 218 259	hormone-refractory prostate cancer (HRPC)
T3	Participants 403 447	380 patients was initiated in men with HRPC.
T4	Participants 454 476	50 randomized patients
T5	Participants 656 671	prostate cancer
